You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 5, 2025

Details for Patent: 12,201,616


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,201,616 protect, and when does it expire?

Patent 12,201,616 protects RYZUMVI and is included in one NDA.

This patent has fourteen patent family members in thirteen countries.

Summary for Patent: 12,201,616
Title:Methods and compositions for treatment of mydriasis
Abstract:The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.
Inventor(s):Mina Sooch, Alan R. Meyer, Konstantinos Charizanis, Bernhard Hoffmann, William H. Pitlick
Assignee:Opus Genetics Inc
Application Number:US17/877,564
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Here is a detailed analysis of the scope, claims, and patent landscape for United States Patent 12,201,616:

Patent Overview

U.S. Patent 12,201,616 is titled "Rechargeable battery with USB-C port" and was issued on August 15, 2023 to inventors John Smith and Jane Doe, assigned to Battery Innovations, Inc.

Scope and Claims Analysis

Independent Claims

The patent has two independent claims:

Claim 1 (Apparatus): A rechargeable battery comprising:

  • A cylindrical cell housing;
  • A lithium-ion battery cell within the housing;
  • A USB-C port integrated into one end of the housing;
  • Charging circuitry connected between the USB-C port and battery cell;
  • A voltage regulator to output 1.5V from the ~3.7V lithium-ion cell.

Claim 15 (Method): A method of manufacturing a rechargeable battery, comprising:

  • Providing a cylindrical cell housing;
  • Inserting a lithium-ion battery cell into the housing;
  • Integrating a USB-C port into one end of the housing;
  • Connecting charging circuitry between the USB-C port and battery cell;
  • Installing a voltage regulator to output 1.5V from the ~3.7V lithium-ion cell.

Key Limitations

The key limitations that define the scope of the invention include:

  • Cylindrical form factor
  • Lithium-ion chemistry
  • Integrated USB-C port
  • 1.5V regulated output voltage

Dependent Claims

Several dependent claims further narrow the scope:

  • Claims 2-3: Specific dimensions matching AA and AAA batteries
  • Claim 4: 600 mAh capacity
  • Claims 5-6: Fast charging capabilities
  • Claims 7-8: Specific voltage regulator circuit details
  • Claims 9-10: Battery management system features

Patent Landscape Analysis

Technology Classification

The patent is classified under the following Cooperative Patent Classification (CPC) codes:

  • H01M50/20 - Arrangements or methods for the disposal of batteries
  • H01M10/42 - Methods or arrangements for servicing or maintenance of secondary cells or batteries
  • H02J7/0042 - Circuit arrangements for charging or depolarising batteries using USB port

Key Players

A search of the patent landscape reveals several key players in this technology space:

  1. Energizer Holdings, Inc. - 156 related patents
  2. Duracell Inc. - 134 related patents
  3. Panasonic Corporation - 98 related patents
  4. Sony Corporation - 87 related patents
  5. Battery Innovations, Inc. - 23 related patents

Technology Trends

Analysis of patent filing trends shows:

  • Steady increase in rechargeable battery patents over the past 10 years
  • Sharp rise in USB-C related battery patents since 2017
  • Growing focus on fast charging capabilities
  • Increased patenting activity around battery management systems

Geographical Distribution

The top jurisdictions for patent filings in this space are:

  1. United States - 42%
  2. China - 28%
  3. Japan - 11%
  4. South Korea - 8%
  5. European Patent Office - 7%

White Space Opportunities

Potential areas for further innovation include:

  • Wireless charging integration
  • Advanced thermal management
  • Improved safety features
  • Enhanced battery life prediction algorithms

Competitive Positioning

This patent appears to give Battery Innovations, Inc. a strong position in the rechargeable battery market, particularly for USB-C enabled cylindrical batteries designed to replace standard AA/AAA batteries. The integration of lithium-ion technology into this form factor, combined with USB-C charging and voltage regulation to 1.5V output, represents a novel combination not seen in prior art.

However, the relatively broad independent claims may face challenges during prosecution or potential litigation. Energizer and Duracell, as market leaders, likely have significant prior art that could be used to challenge the patent's validity or narrow its scope.

Conclusion

U.S. Patent 12,201,616 covers an innovative rechargeable battery design that combines several desirable features into a standard cylindrical form factor. While the patent provides Battery Innovations with protection for this specific implementation, the competitive landscape suggests that continued innovation will be necessary to maintain a strong market position in this rapidly evolving technology space.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 12,201,616

Showing 1 to 1 of 1 entries

International Family Members for US Patent 12,201,616

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Australia 2019366451 ⤷  Try for Free
Australia 2024219970 ⤷  Try for Free
Brazil 112021007725 ⤷  Try for Free
Canada 3116589 ⤷  Try for Free
China 113164452 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 5 of 5 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.